FIGURE 2 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Serum phosphate by KIN-3248 C1D1 exposure. Baseline and on-treatment serum phosphate were measured locally in all 54 participants. A, Scatter plot of serum phosphate (mg/dL) after approximately 1 week on KIN-3248 by KIN-3248 C1D1 exposure (AUC0–24). Significant correlation between KIN-3248 exposure and serum phosphate level after approximately 1 week of treatment (nominal C1D8: actual study days 6, 7, 8 or 9). Linear fit with SE. Pearson R = 0.55, P = 1.7e-5. B, Scatter plot of initial change in serum phosphate by KIN-3248 C1D1 exposure (AUC0–24). Significant correlation between C1D1 KIN-3248 exposure and the initial change (∼1 week) in serum phosphate (PhosC1D8 – PhosC1D1). Pearson R = 0.62, P = 7.1e-7. One participant was missing the C1D1 phosphate measurement, so the screening measurement was used as the baseline value for that participant.